LPXN

Across TCGA pan-cancer cohorts, LPXN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LPXN data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LPXN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LPXN expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and SKCM are the cancer types where LPXN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.122	0.626	.001	24	view →
UCEC	DFS	Median	All	1.000	0.829	.018	16	view →
SKCM	DFS	Median	All	0.251	0.760	.003	9	view →
SCLC	DFS	Median	All	0.233	0.630	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LPXN–BLCA (DFS)

Open the BLCA breakdown →